Leap Therapeutics (LPTX) Prices $90M Share and Warrant Offering at $2.85/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
After-Hours Stock Movers 09/21: (MRIN) (SFIX) Higher; (SMMT) (LPTX) (FDX) Lower (more...)
September 21, 2021 6:04 PM EDTAfter-Hours Movers:
Marin Software (NASDAQ: MRIN) 74% HIGHER; entered into a Revenue Share Agreement with Google LLC for the Company to develop its enterprise tech platform and software products.
Summit Therapeutics (NASDAQ: SMMT) 19.8% LOWER; received feedback from the United States Food and Drug Administration (the FDA) that the FDA does not agree with the change to the primary endpoint that Summit proposed and has subsequently implemented in its ongoing Phase III Ri-CoDIFy studies when combining the... More
Leap Therapeutics (LPTX) Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
September 21, 2021 4:02 PM EDTLeap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock, Leap intends to offer and sell to certain investors pre-funded... More
Leap Therapeutics (LPTX) PT Raised to $5 at Piper Sandler Following Positive Data at ESMO
September 20, 2021 8:34 AM EDTPiper Sandler analyst Tyler Van Buren raised the price target on Leap Therapeutics (NASDAQ: LPTX) to $5.00 (from $4.00) while maintaining an Overweight rating following data presented at ESMO from the DisTinGuish study in 1st-line G/GEJ cancer that featured two KOLs.
The analyst... More
